The Association of Southeast Asian Nations (ASEAN) has signed the ASEAN Sectoral Mutual Recognition Agreement for Good Manufacturing Practice Inspection of Manufacturers of Medicinal Products, at a summit in Pattaya, Thailand, shortly before the 14th summit of the regional group was broken up by local anti-government protesters. The document highlights the importance of deeper economic integration between the ASEAN's members with an economic community intended to be realized by 2015.
The Agreement calls for the mutual recognition of GMP certification and inspection reports by each of the 10 member states' competent authorities. A statement issued by the ASEAN Secretariat noted that "these certificates and/or reports will be used as the basis for regulatory actions such as the granting of approvals or licenses to the manufacturer, supporting post-market assessments of conformity of these products and providing information on the manufacturer's facilities including the testing laboratories, if any, or its contracted laboratory."
Among the benefits that the regional association hopes to result from the agreement are: raising the focus of manufacturers on safety and quality; boosting international recognition of ASEAN members' regulatory oversight of medicine production; savings to drugmakers by reducing the duplication of approval procedures from one country to another; and consumers obtaining the assurance that approved products are safe to use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze